Company Overview and News
WASHINGTON (Reuters) - Senate Republican Leader Mitch McConnell on Wednesday prodded President Donald Trump’s administration to quickly resolve festering trade disputes particularly with China, saying tariffs imposed by other countries in response to Trump’s trade policies are starting to pinch the “red hot” U.S. economy.
TM 7203 TYT TOYOF
NEW YORK – Uber Technologies Inc. is eyeing a valuation above $100 billion for its much-anticipated share offering due in 2019, which would be the biggest-ever in the tech sector, sources familiar with the plan said Tuesday.
DGLD TM SFTBF CS GS GLSSP UGLD JEF MS GM SFTBY JBK DSLV VIIX GSC CSSLF VIIZ TFG TYT TOYOF GSJ CSGKF 7203 ZIV USLV 9984 TVIX GJS XIV
Uber Technologies Inc could be valued at $120 billion when it finally goes public next year according to recent proposals made by US banks, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.
TM 7203 TYT MS TOYOF
Uber may be launching a mega Rs $120 billion initial public offering (IPO) by next year. Or, maybe not. Wall Streets bankers have sent proposals to the ride-hailing company valuing it at a whopping $120 billion for an IPO that could take place early next year, according to a report by Wall Street Journal.
TM 7203 TYT MS TOYOF
Uber has labored through a series of scandals, from claims of workplace sexual harassment to the alleged theft of trade secrets from rival Alphabet
TM GOOG GS GLSSP GM JBK GSC TFG TYT TOYOF GSJ GOOGL 7203 GJS
The sōgō shōsha‘s organization and business model is unique to Japan. This is, for the most part, because they are a reflection of Japan’s own unique economic development, first during the Meiji Restoration’s period of rapid industrialization and commercialization aimed at building a strong military in the latter half of the 19th century and then in the intensive rebuilding of Japan’s infrastructure and industry in the aftermath of World War II eventually leading to Japan’s transformation as an economic superpower.
ITOCY TM TYHOF TYT TOYOF SZHFF MMTOY ITOCF 7203 MARUF 8015 SSUMF 7211 MMTOF
On October 9, Microsoft (NASDAQ:MSFT) announced a partnership with Grab, the Singapore-based ride-hailing service which has supplanted Uber in Southeast Asia. The deal should boost Microsoft stock over the longer term.
IBM FB TM TYT GOOG SFTBF TOYOF BABA AMZN GOOGL 7203 MSFT 9984 SFTBY
CHIBA – Toyota Motor Corp. and messaging app provider Line Corp. said Monday they will offer an artificial intelligence platform featuring voice commands for navigation services in Toyota cars in Japan by next summer.
TM 7203 TYT TOYOF LN
TOKYO, Oct 15 (Reuters) - Japan’s Nikkei ended at an eight-week low on Monday as automakers and other manufacturers were hit by news that Washington would seek a provision about currency manipulation in future trade deals, including with Japan.
DKILF DKILY TM 7203 TYT 6367 TOYOF
TOKYO, Oct 15 (Reuters) - Japan’s Nikkei fell to a five-week low on Monday as automakers and other manufacturers were hit by the U.S. Treasury Secretary’s comment that Washington wants provisions to deter currency manipulation in its foreign trade deals.
DKILF DKILY TM 7203 TYT 6367 TOYOF
2018-10-12 zacks - 1
Chicago, IL –October 12, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Honda Motor Co., Ltd. (HMC - Free Report) , General Motors Company (GM - Free Report) , Toyota Motor Corp. (TM - Free Report) , Ford Motor Co.
STLD TM 7203 TYT GM LB TOYOF OUT
China's car sales fell the most in nearly seven years in September, stoking concerns the world's biggest auto market could contract for the first time in decades this year amid cooling economic growth and a biting trade war.
HYUO TM TYT KIMTY TOYOF HYUD VLKAF KIMTF 7203 HYUP GM
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...